PATENTS
IL-1β/MMP-7 treatment of cystitis:
Claims cover the use of IL-1β inhibitors (such as Anakinra) and/or MMP-7 inhibitors in the treatment of cystitis.
NKR1 antagonists:
Claims cover the use of NK1R antagonists alone or in combination with Anakinra in the treatment of infections.
IRF7 inhibition:
IRF-7 inhibitors and in particular, siRNA molecules are effective in the treatment of bacterial infections and in particular, kidney infections. Broader claims should be allowed.
Pol II inhibitors:
Claims cover the use of named substances from commensal bacteria to be exploited in immunosuppression as well as in anti-inflammatory and anti-infective therapies.
| Title | Filing Date | Country | Patent | Comments |
| IL-1β / MMP-7 treatment of cystitis |
January 2016 | Australia | 2016205864 | IL-1β inhibitors (such as Anakinra) and/or MMP-7 inhibitors in the treatment of cystitis. |
| Europe | 16703357.0 and 9186921.3 | |||
| USA | 15/542,041 | |||
| NK1R antagonists |
June 2017 | Australia | 2017292391 | NK1R antagonists alone or in combination with Anakinra in the treatment of infections. |
| Europe | 17740488.6 | |||
| USA | 16/316,324 | |||
| IRF7 inhibition |
March 2016 | Australia | 2016241555 | IRF-7 inhibitors and in particular, siRNA molecules are effective in the treatment of bacterial infections and in particular, kidney infections. |
| Europe | 16715897.1 | |||
| USA | 10,287,585 (granted) | |||
| Pol II inhibitors |
October 2017 | Australia | 2017344453 | Named substances from commensal bacteria to be exploited in immunosuppression as well as in anti-inflammatory and anti-infective therapies. |
| Europe | 17797991.1 | |||
| India | 20194718316 | |||
| Singapore | 11201903336U | |||
| USA | 16/341,962 | |||
| UPEC inhibitors |
October 2017 | Australia | 2017342234 | This application is directed to the use of anti-inflammatory molecules from bacteria. |
| Europe | 17794419.6 | |||
| India | 201947018317 | |||
| Singapore | 11201903297R | |||
| USA | 16/341,248 |
